Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Kun Hu, Meiju Zhang, Dongdong Wu, Yuxuan Xie & Jie Ren. (2020) A Novel Synthesis of Pimavanserin: A Selective Serotonin 5-HT2A Receptor Inverse Agonist. Organic Preparations and Procedures International 52:1, pages 69-76.
Read now
Read now
Yasaman Kianirad & Tanya Simuni. (2017) Pimavanserin, a novel antipsychotic for management of Parkinson’s disease psychosis. Expert Review of Clinical Pharmacology 10:11, pages 1161-1168.
Read now
Read now
Ines Chendo & Joaquim J Ferreira. (2016) Pimavanserin for the treatment of Parkinson’s disease psychosis. Expert Opinion on Pharmacotherapy 17:15, pages 2115-2124.
Read now
Read now
Joseph H. Friedman & Umer Akbar. (2016) Psychosis in Parkinson’s disease: unexplained observations in a seemingly simple model. Expert Review of Neurotherapeutics 16:6, pages 595-596.
Read now
Read now
Ricardo P. Garay, Michel Bourin, Evelyne de Paillette, Ludovic Samalin, Ahcène Hameg & Pierre-Michel Llorca. (2016) Potential serotonergic agents for the treatment of schizophrenia. Expert Opinion on Investigational Drugs 25:2, pages 159-170.
Read now
Read now
Umer Akbar & Joseph H Friedman. (2015) Recognition and treatment of neuropsychiatric disturbances in Parkinson’s disease. Expert Review of Neurotherapeutics 15:9, pages 1053-1065.
Read now
Read now
Rebekah J Jakel & Mark Stacy. (2014) Parkinson’s disease psychosis. Journal of Parkinsonism and Restless Legs Syndrome 4, pages 41-51.
Read now
Read now
Martin Broadstock, Clive Ballard & Anne Corbett. (2014) Novel pharmaceuticals in the treatment of psychosis in Parkinson’s disease. Expert Review of Clinical Pharmacology 7:6, pages 779-786.
Read now
Read now
Leora L Borek & Joseph H Friedman. (2014) Treating psychosis in movement disorder patients: a review. Expert Opinion on Pharmacotherapy 15:11, pages 1553-1564.
Read now
Read now
Articles from other publishers (23)
Mattia Ferraiolo & Emmanuel Hermans. (2023) The complex molecular pharmacology of the dopamine D2 receptor: Implications for pramipexole, ropinirole, and rotigotine. Pharmacology & Therapeutics 245, pages 108392.
Crossref
Crossref
Jitendra Kumar Sinha, Punya Sachdeva, Faizan Ahmad, Jasmine Sarkar, Raafiah Izhar, Ayesha Rahman & Shampa Ghosh. 2023. Cognizance of Schizophrenia:: A Profound Insight into the Psyche. Cognizance of Schizophrenia:: A Profound Insight into the Psyche
149
179
.
Luis Agüera-Ortiz, Ganesh M. Babulal, Marie-Andrée Bruneau, Byron Creese, Fabrizia D’Antonio, Corinne E. Fischer, Jennifer R. Gatchel, Zahinoor Ismail, Sanjeev Kumar, William J. McGeown, Moyra E. Mortby, Nicolas A. Nuñez, Fabricio F. de Oliveira, Arturo X. Pereiro, Ramit Ravona-Springer, Hillary J. Rouse, Huali Wang & Krista L. Lanctôt. (2022) Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions. Journal of Alzheimer's Disease 88:4, pages 1203-1228.
Crossref
Crossref
Dean G. Brown & Heike J. Wobst. (2022) A survey of the clinical pipeline in neuroscience. Bioorganic & Medicinal Chemistry Letters 56, pages 128482.
Crossref
Crossref
Joshua T. Kantrowitz. (2020) Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches. CNS Drugs 34:9, pages 947-959.
Crossref
Crossref
Sarah Horn, Hayley Richardson, Sharon X. Xie, Daniel Weintraub & Nabila Dahodwala. (2019) Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. Parkinsonism & Related Disorders 69, pages 119-124.
Crossref
Crossref
Dalil Cherif Mghari. (2019) Mécanisme d’action de la pimavansérine : le nouvel antipsychotique pour traiter la psychose parkinsonienne. Annales Médico-psychologiques, revue psychiatrique 177:10, pages 1010-1012.
Crossref
Crossref
Jingjing Zhu, Weihong Hou, Yong Xu, Feng Ji, Guowei Wang, Ce Chen, Chongguang Lin, Xiodong Lin, Jie Li, Chuanjun Zhuo & Mingjng Shao. (2019) Antipsychotic drugs and sudden cardiac death: A literature review of the challenges in the prediction, management, and future steps. Psychiatry Research 281, pages 112598.
Crossref
Crossref
Geetha Bhavani Koduri, Hari Babu BollikollaRamachandran DittakaviSrinivasu Navuluri. (2018) Quantification of Pimavanserin in Bulk and Tablet Dosage Form Using A Stability Indicating High Performance Liquid Chromatographic Method. Pharmaceutical Sciences 24:4, pages 291-297.
Crossref
Crossref
Joseph H. Friedman. (2018) Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart Review. Clinical Neuropharmacology 41:5, pages 156-159.
Crossref
Crossref
Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, Sarah J. Fink & Christopher J. O’Donnell. (2018) Synthetic Approaches to New Drugs Approved During 2016. Journal of Medicinal Chemistry 61:16, pages 7004-7031.
Crossref
Crossref
Wenying Wu, Yanjie Chu, Shixiao Wang, Xiaoyang Sun, Jingjing Zhang, Yannian Wang & Xiaohui Chen. (2018) Investigation of metabolic profile of pimavanserin in rats by ultrahigh-performance liquid chromatography combined with Fourier transform ion cyclotron resonance mass spectrometry. Rapid Communications in Mass Spectrometry 32:3, pages 269-276.
Crossref
Crossref
Matthias M. Herth & Gitte M. Knudsen. 2018. 5-HT2A Receptors in the Central Nervous System. 5-HT2A Receptors in the Central Nervous System
85
134
.
Joseph H. Friedman. (2017) A Retrospective Study of Pimavanserin Use in a Movement Disorders Clinic. Clinical Neuropharmacology 40:4, pages 157-159.
Crossref
Crossref
Rita Santos, Oleg Ursu, Anna Gaulton, A. Patrícia Bento, Ramesh S. Donadi, Cristian G. Bologa, Anneli Karlsson, Bissan Al-Lazikani, Anne Hersey, Tudor I. Oprea & John P. Overington. (2016) A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery 16:1, pages 19-34.
Crossref
Crossref
Harini Sarva & Claire Henchcliffe. (2016) Evidence for the use of pimavanserin in the treatment of Parkinson’s disease psychosis. Therapeutic Advances in Neurological Disorders 9:6, pages 462-473.
Crossref
Crossref
Stephen M. Stahl. (2016) Parkinson’s disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectrums 21:5, pages 355-359.
Crossref
Crossref
Stephen M. Stahl. (2016) Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. CNS Spectrums 21:4, pages 271-275.
Crossref
Crossref
Anna Bielenica, Ewa Kędzierska, Michał Koliński, Sebastian Kmiecik, Andrzej Koliński, Ferdinando Fiorino, Beatrice Severino, Elisa Magli, Angela Corvino, Ilaria Rossi, Paola Massarelli, Anna E. Kozioł, Aleksandra Sawczenko & Marta Struga. (2016) 5-HT 2 receptor affinity, docking studies and pharmacological evaluation of a series of 1,3-disubstituted thiourea derivatives. European Journal of Medicinal Chemistry 116, pages 173-186.
Crossref
Crossref
Joseph H. Friedman. 2016. Parkinson's Disease. Parkinson's Disease
127
138
.
. 2016. Parkinson's Disease. Parkinson's Disease
93
174
.
Valdemar L. Andersen, Hanne D. Hansen, Matthias M. Herth, Agnete Dyssegaard, Gitte M. Knudsen & Jesper L. Kristensen. (2015) 11C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand. Bioorganic & Medicinal Chemistry Letters 25:5, pages 1053-1056.
Crossref
Crossref
Jennifer G. Goldman & Samantha Holden. (2014) Treatment of Psychosis and Dementia in Parkinson’s Disease. Current Treatment Options in Neurology 16:3.
Crossref
Crossref